Galectin Therapeutics Inc. Common Stock (GALT)
Stock · NASDAQ · Health Care
$3.62as of 10/16/2026
Price chart
Active signals
GALT Signal Track Record
How signals performed across all stocks →What GALT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | 0.0% | 49% | September 18, 2026 |
| Bollinger Band Breakout | 28 | -3.2% | 46% | August 24, 2026 |
| Bollinger Band Breakdown | 21 | +1.8% | 57% | July 22, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -2.0% | 40% | August 18, 2026 |
| Any 20-session window (baseline) | +0.5% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hyperte…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 9
- Website
- galectintherapeutics.com/
Fundamentals
- 1-day range
- $3.61$3.86
- Market cap
- $324.74M
- P/E (trailing)
- —
- P/E (forward)
- -2.17
- EPS (trailing)
- $-0.43
- Dividend yield
- —
- Beta
- 0.49
- Avg. volume
- 328.5K
Forecasts
1 analyst ratings
Galectin Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
- FHTXFoghorn Therapeutics Inc. Common Stock$1.85▼ 2.12%Market cap $327.04MP/E —$1.79$7.61
- CATXPerspective Therapeutics Inc. Common Stock$2.17▼ 7.26%Market cap $338.72MP/E —$1.96$6.16
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1▼ 9.91%Market cap $310.11MP/E 84.95$1.13$7.08
- VNDAVanda Pharmaceuticals Inc. Common Stock$4.03▼ 4.95%Market cap $307.59MP/E —$4.27$9.94
- IRDOpus Genetics Inc. Common Stock$3.84▼ 5.19%Market cap $307.14MP/E —$1.7$7.07
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $1.85 | ▼ 2.12% | $1.79$7.61 |
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $2.17 | ▼ 7.26% | $1.96$6.16 |
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $310.11M | 84.95 | $1 | ▼ 9.91% | $1.13$7.08 |
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $307.59M | — | $4.03 | ▼ 4.95% | $4.27$9.94 |
| IRD Opus Genetics Inc. Common Stock | $307.14M | — | $3.84 | ▼ 5.19% | $1.7$7.07 |
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · 9/15/2026
Insider Activity
Insider Actions →- Richard E. Uihlein · July 31, 2026 · Option Exercise0 @ $95,475,704
- Richard E. Uihlein · July 31, 2026 · Option Exercise2.55M @ $4.05
- Richard E. Uihlein · July 31, 2026 · Option Exercise31.83M @ $3
- Khurram Jamil · July 14, 2026 · Option Exercise16.3K @ $3.04
- Khurram Jamil · July 14, 2026 · Sale16.3K @ $5.13
- Khurram Jamil · June 23, 2026 · Option Exercise7.6K @ $1.23
- Khurram Jamil · June 23, 2026 · Sale7.6K @ $3.14
- Khurram Jamil · May 26, 2026 · Option Exercise568 @ $1.23
- Khurram Jamil · May 26, 2026 · Sale568 @ $3.1
Institutional Ownership
March 31, 2026
- Total shares held
- 15.14M
- Total value held
- $41.35M
- Institutional holders
- 97
- Unknown1.97M
- Unknown1.22M
- Unknown1.12M
- Unknown1.07M
- Unknown800.0K
- Unknown799.2K
- Unknown798.4K
- Unknown721.8K
- Unknown612.8K
- Unknown467.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.